Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 372Neoplasms 325Neoplasm Metastasis 288Leukemia, Myeloid, Acute 280Breast Neoplasms 272Colorectal Neoplasms 239Melanoma 193Ovarian Neoplasms 190Recurrence 184Multiple Myeloma 178Prostatic Neoplasms 158Lung Neoplasms 158Pancreatic Neoplasms 151Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 147Glioblastoma 146Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 115Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 109Brain Neoplasms 105Advanced Solid Tumors 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma, Large B-Cell, Diffuse 102Lymphoma 102Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Lymphoma, Follicular 92Endometrial Neoplasms 92

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroendocrine Neoplasms × 1 year × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡